Alan J. Kivitz, MD: Phase 2b Data on TAK-279 for Psoriatic Arthritis

During this interview, Dr. Kivitz explained the background and key findings of his team’s research on TAK-279, a selective oral TYK2 inhibitor.

Related Keywords

California ,United States ,San Diego ,Alanj Kivitz , ,Clinical Research ,American College Of Rheumatology ,Altoona Center ,Altoona Arthritis Osteoporosis Center ,Altoona Arthritis ,American College ,Racr ,Psoriatic Arthritis ,Tak 279 ,Phase 2b ,